G
Guillaume Wendt
Researcher at Novartis
Publications - 3
Citations - 31
Guillaume Wendt is an academic researcher from Novartis. The author has contributed to research in topics: Fingolimod & Bradycardia. The author has an hindex of 2, co-authored 3 publications receiving 23 citations.
Papers
More filters
Journal ArticleDOI
Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study
Volker Limmroth,Tjalf Ziemssen,Michael Lang,Stephan Richter,Bert Wagner,Judith Haas,Stephan Schmidt,Kathrin Gerbershagen,Christoph Lassek,Luisa Klotz,Olaf Hoffmann,Christian Albert,Katrin Schuh,Monika Baier-Ebert,Guillaume Wendt,Heinke Schieb,Susanne Hoyer,Ralf Dechend,Wilhelm Haverkamp +18 more
TL;DR: Continuous Holter ECG monitoring in this large real-life cohort revealed that bradycardia and AV conduction abnormalities were rare, transient and benign.
Journal ArticleDOI
Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study.
Ralf A. Linker,Guillaume Wendt +1 more
TL;DR: It is confirmed that the first-dose observation after fingolimod initiation is usually uneventful (even in patients with pre-existing cardiovascular risk factors of this cohort) and that the rarely observed events remained asymptomatic and self-limited.
Journal ArticleDOI
A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose-Possible Predictors of Cardiac Outcomes.
Volker Limmroth,Tjalf Ziemssen,Ingo Kleiter,Bert Wagner,Stephan Schmidt,Christoph Lassek,Monika Baier-Ebert,Guillaume Wendt,Ralf Dechend,Wilhelm Haverkamp +9 more
TL;DR: In this paper, a large-scale study of 6,998 patients with relapsing remitting multiple sclerosis (RRMS) showed that transient bradycardia and conduction abnormalities during the observation phase are rare, benign and reversible.